Announcements
Drinks
24/4/2024 Research EN
Norwegian Savings Banks: strong profitability set to continue
Norwegian savings banks have displayed strong profitability on the back of the supportive interest-rate environment. We expect this to continue. The pace of credit expansion has abated but the banks have managed to continue growing their loan books.
24/4/2024 Research EN
EU banks NPL Heatmaps: modest increases to continue
Non-performing loans (NPLs) of EU banks continued to increase, hitting EUR 364.9bn according to the EBA’s latest Risk Dashboard showing data to Q4 2023. But the consolidated NPL ratio, at 1.85%, is still close to the historical low.
22/4/2024 Research EN
The Wide Angle: Bank analysis needs to move with the times
When it comes to assessing banks, high customer satisfaction, progress in digitalisation or brand value do not win arguments in investment, credit, or rating committees if financial metrics are not sufficiently reassuring.
17/4/2024 Research EN
Covered Bond Quarterly: Have German banks put Pfandbriefe at risk?
After a strong January, EUR benchmark covered bond issuance slowed in February and March. Some of the reluctance to issue may have been driven by Germany’s specialised commercial mortgage lenders, given rising tensions in commercial real estate.
11/4/2024 Research EN
French banks quarterly: Heading into a more volatile business environment
Stalling economic growth in France could herald a more difficult period for French banks. Lacklustre fourth-quarter bank results, which already cast a shadow over otherwise satisfactory full-year performance, look increasingly less like an anomaly.
10/4/2024 Research EN
Germany’s auto parts sector: defaults point to consolidation in cyclical downturn rather than crisis
Multiple bankruptcies in Germany’s automotive parts sector since mid-2023 are less a sign of a sector-wide crisis than the impact of a cyclical downturn and tight credit conditions on suppliers with financial and commercial weaknesses.
5/4/2024 Research EN
Scope publishes final rating methodology for Pharmaceutical Companies’ Rating Methodology
The methodology is now final following a call-for-comments period and will apply to all issuer and debt ratings of corporates in the sector. The application of the updated methodology will not trigger any rating changes.